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Abstract: Suicidal behavior (SB) represents a major public health issue. Clinical and basic research 
suggests that SB is a specific entity in psychiatric nosology involving a combination of personality 
traits, genetic factors, childhood abuse and neuroanatomical abnormalities. The principal risk factor 
for suicide is depression. More than 60% of patients who complete suicide are depressed at the time 
of suicide, most of them untreated. There has been a controversy concerning a possible increased 
risk of SB in some depressed patients treated with antidepressants. Most recent evidence suggests, 
however, that treatment of depressed patients is associated with a favorable benefit-risk ratio. A 
recent study has determined the effects of 6 weeks of antidepressant treatment with the serotonin 
and norepinephrine reuptake inhibitor, milnacipran, on suicidality in a cohort of 30 patients with 
mild to moderate depression. At baseline, mild suicidal thoughts were present in 46.7% of patients. 
Suicidal thoughts decreased progressively throughout the study in parallel with other depressive 
symptoms and were essentially absent at the end of the study. At no time during treatment was 
there any indication of an increased suicidal risk. Retardation and psychic anxiety decreased in 
parallel possibly explaining the lack of any “activation syndrome” in this study.
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Introduction
Suicidal behavior represents a major public health issue. Suicide is among the 10 
leading causes of death for all ages.1 Every year more than 100,000 men and women 
commit suicide in Europe2 and the World Health Organization estimates that there 
will be about 1.5 million deaths by suicide per year worldwide by 2020.3
Suicide and depression
Mental disorders, especially depression, are present in more than 90% of suicides, 
and over 80% are untreated at the time of death.4,5 An often-quoted figure is that about 
15% of patients with major depression will eventually die by suicide.6 This estimation 
was, however, derived largely from studies of severely depressed inpatients. A lifetime 
suicide risk of about 6% has been calculated for all depressed patients.7 The discrepancy 
between these figures may be erroneously interpreted as evidence that overt suicidal 
behavior occurs almost exclusively in severe depression, a notion which can lead to 
inappropriate management of less severely depressed patients. There is, however, 
clear evidence that suicidality (thoughts and behavior) is associated with any type of 
depressive disorder and any degree of severity.8,9Neuropsychiatric Disease and Treatment 2010:6(Suppl 1) submit your manuscript | www.dovepress.com
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The increased use of pharmacological treatments in 
  psychiatric diseases has had only a small effect at decreasing 
the rates of attempted and completed suicides over recent 
years.10 There is therefore a pressing need to revisit suicide 
prevention strategies in order to promote action specifically 
directed towards potential suicide victims. To achieve this 
goal, suicide prevention strategies require the identification 
of specific therapeutic targets. Using this approach, patients 
at risk of suicide could benefit from specific treatments, the 
prerequisite being to consider suicidal behaviour (SB) as a 
specific disorder.11
Suicidal behavior as  
a specific disorder
Epidemiological and clinical data led to the proposition of 
a stress vulnerability model for suicidal behavior.12 Indeed, 
from psychological autopsy studies, we know that virtually 
all subjects who completed suicide were suffering from a 
psychiatric disorder at the time of their suicide. We also 
know from the notes left by these subjects before their death, 
that environmental stresses are common triggers of suicidal 
behavior. However, only a minority of individuals who are 
faced with such adversities, resort to suicidal behavior. In 
this model, it is postulated that among people suffering from 
a psychiatric disorder and submitted to stressful life events, 
those who attempt suicidal acts have a specific vulnerability. 
One indicator of such vulnerability is the fact that the main 
risk factor of a suicidal behavior is the existence of a history 
of suicide attempts.
To summarize findings from both cross sectional and 
longitudinal studies, the vulnerability to suicidal behavior is 
associated with a personal and a family history of suicidal 
behavior, the existence of childhood maltreatment, and 
personality traits related to both impulsive aggression and 
hopelessness.13
Very strong support of the vulnerability stress model has 
come from the widely replicated findings showing that a sero-
tonergic dysfunction is a trait marker of suicidal behavior.14 
Recently, by using the neuroscientific toolbox, it has been 
possible to add evidence of a specific neurobiological vulner-
ability to suicidal behavior. Over the last 15 years, molecular 
genetic studies have identified a number of genetic polymor-
phisms associated with suicidal behavior, mainly modulating 
the effect of life stresses or childhood abuse.15,16
Neuropsychology and brain imaging are valuables tools 
to investigate in vivo brain functioning. Understanding cogni-
tive dysfunctions and their underlying neural basis can shed 
light on the pathophysiology of vulnerability to SB. In a series 
of studies, we found that decision-making impairment was a 
cognitive vulnerability trait of SB, independently from any 
psychiatric disorders.17 Moreover, decision-making is modu-
lated by serotonergic genotypes associated with the vulner-
ability to SB, and related to a dysfunction of the orbitofrontal 
cortex.18 According to the somatic marker hypothesis,19 an 
electrodermal response, reflecting the emotional arousal, is 
necessary to guide decision-making in healthy subjects.20
In the first fMRI study in SB, we found that in comparison 
to male patients with no history of suicide attempts, male 
suicide attempters had higher activation of the right orbitof-
rontal cortex in response to viewing angry vs neutral faces.21 
These data, together with those from other brain imaging 
studies, suggest that the orbitofrontal region may play a key 
role in the vulnerability to SB, mediating the involvement 
of emotional dysregulation.
Based on these findings, a general model has been pro-
posed postulating that interactions between genes and child-
hood abuse alter the functioning of the serotonergic system 
and HPA axis. These biochemical impairments translate into 
personality traits related to impulsive aggression, neuroti-
cism or hopelessness, which confer vulnerability to SB that 
is expressed in the context of aversive events.
The demonstration of the existence of psychobiological 
abnormalities involved in vulnerability to SB, independent 
of related psychiatric disorders, led to a historic turning 
point in suicidology. Indeed, foremost researchers in the 
field have advocated considering SB as an entity per se 
in the psychiatric nosology. Indeed, there is now robust 
evidence that SB conforms well to the criteria proposed by 
Robins and Guze22 for establishing the validity of clinical 
syndromes.11 In a further step, Oquendo et al23 recently rec-
ommended “that suicidal behavior be considered a separate 
diagnostic category” in the future version of the Diagnostic 
and Statistical Manual of Mental Disorders. Their proposal 
would be advantageous to patients, since “practically, an axis 
for suicidal acts would compel clinical and administrative 
structures to determine the suicide risk status of individuals 
assessed in psychiatric settings”.
Do antidepressants increase  
the risk of suicide?
Antidepressant therapy, which is effective in managing the 
symptoms of major depressive disorder, is expected to reduce 
or prevent suicidal behavior associated with depression.24 
Recent randomized controlled trials have, however, raised 
some doubt as to whether antidepressants do, in fact, reduce 
suicidal thoughts and behaviors.25,26 Reports of higher rates of Neuropsychiatric Disease and Treatment 2010:6(Suppl 1) submit your manuscript | www.dovepress.com
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suicide-related adverse events during treatment with selective 
serotonin reuptake inhibitors (SSRIs) and other antidepres-
sants compared to placebo have prompted regulatory bodies 
in the US and Europe to issue warnings alerting clinicians 
to the risk of suicide during the first weeks of antidepressant 
treatment.27,28 These warnings have had an impact on antide-
pressant prescribing and may have paradoxically increased 
the risk of suicide in the depressed population.29
A recent meta-analysis30 of 372 double-blind, random-
ized, placebo-controlled trials involving a total of 99,231 
adults revealed a favorable benefit-risk ratio for treating 
depressed patients with antidepressants with the possible 
exception of those under 25 years of age. The study found 
that the odds ratio for suicidality (ideation or worse) was 
significantly less with antidepressants than with placebo. 
When the data were analyzed by age, all age groups had a 
reduced risk with antidepressants with the single exception 
of patients under 25 years in whom there was a tendency for 
an increased risk of suicidality compared to placebo.
Thus the most recent evidence suggests a favorable 
benefit-risk ratio for treating depressed patients with antide-
pressants with the possible exception of those under 25 years 
of age. Nevertheless patients should be carefully assessed 
during treatment, especially during the first weeks of treat-
ment when an activation syndrome may increase suicidal risk 
in some patients with certain antidepressants.
A study investigating the effect  
of milnacipran on suicidality
In the light of this controversy, the effect of an antidepressant 
on suicidal ideation clearly remains an important question. 
Thus, a recent Russian study,31 in addition to assessing the 
general efficacy and tolerability of milnacipran (Ixel), 
a serotonin and norepinephrine reuptake inhibitor (SNRI)32 
recently introduced into Russia, investigated the effects of 
the drug on the occurrence and intensity of suicidal thoughts 
and behavior in patients with mild to moderate depressive 
disorders.
Of the 30 patients enrolled in the study, 60% had a 
diagnosis of a single depressive episode and the majority 
(86.6%) were moderately depressed with baseline Hamilton 
depression rating score (HDRS17) of 23.9 ± 1.8 and Beck 
depression inventory score (BDI) of 37.7 ± 3.9.
No patients had made any previous suicidal attempts and 
at baseline no plans or preparation for suicide were noted. 
Suicidal ideation was observed, however, in 14 patients 
(46.7%). The mean baseline level of suicidality, as indicated 
by Beck Scale for Suicidal ideation (BSS),33 was 4.9 ± 4.9, 
indicating a mild level of suicidality. A total of 57 suicidal 
manifestations were recorded throughout the study (Table 1). 
The most were thoughts of “inanity of existence (life has no 
meaning)”, thoughts that death could resolve existing suffer-
ings, suicidal thoughts and unwillingness to live.
More rarely, other signs of suicidality were reported such 
as visualization of one’s own suicide, death or funeral, as 
well as a supraliminal death instinct. Only in a few patients 
did these suicidal ideations develop into either compulsive 
thoughts of death and funerals or suicidal fantasies.
Milnacipran was administered for 2 to 3 days, at 25 to 
50 mg/day depending on the severity of depressive symptoms 
and then increased to 100 mg/day (50 mg twice daily). The 
antidepressant efficacy of the milnacipran treatment was 
demonstrated by the steady reduction of the mean HDRS17 
score throughout the study (Figure 1). Statistically significant 
differences compared to baseline occurred from the first 
week of therapy. At endpoint (after 6 weeks of treatment) 
mean HDRS17 was 9.5 ± 4.4 with 60% of patients classified 
as treatment responders (reduction of baseline HDRS17 of 
at least 50%).
Suicidality as measured by the BSS decreased rapidly 
with a significant reduction observed from the second week 
of treatment (Figure 1). After 4 weeks of treatment, mean 
BSS scores were close to zero indicating a virtual absence of 
suicidality in treated patients. None of the patients showed 
any increase, even transitory, in BSS score during milnacipran 
treatment indicating an absence of any “activation syndrome”, 
Table 1 Suicidal manifestations (thoughts and behavior) reported 
during the study
Number of patients 
reportinga
% Of all reported 
suicidal thoughts  
and behavior
Thoughts of inanity  
of existence 
11 19.4
Thoughts of death 9 15.8
Thoughts of suicide 7 12.3
Unwillingness to live 6 10.5
visions of suicide 5 8.8
visions of death 4 7.0
visions of funerals 4 7.0
Death instinct 4 7.0
Suicidal fantasies 2 3.5
Compulsive thoughts  
of suicide 
2 3.5
Compulsive thoughts  
of funerals 
2 3.5
Compulsive thoughts  
death 
1 1.7
aSome patients reported more than one suicidal manifestations.Neuropsychiatric Disease and Treatment 2010:6(Suppl 1) submit your manuscript | www.dovepress.com
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sometimes observed at the early stages of therapy with certain 
antidepressants.8 Even the occurrence in some patients of 
anxiety as an adverse event during milnacipran therapy did not 
negatively affect the general suicidality of these patients.
Analysis of the “suicidal thoughts/attempts” item of the 
HDRS17 (item 3) at baseline showed a score of 1 in 10 patients 
(33.3%) and of 2 in one patient. The number of patients with 
scores 1 or 2 decreased progressively throughout the study. 
At endpoint only 3 patients had a score of 1.
The HDRS17 items of “psychic anxiety” (item 10) and 
“retardation” (item 8) showed a similar and parallel progres-
sive reduction throughout the study (Figure 2). At the end 
of the study anxiety was reduced by 82% and retardation by 
88%. The fact that the anxiety/retardation ratio remained 
approximately constant during milnacipran therapy probably 
explains the absence of any “activation syndrome”.
The wide prevalence of different suicidal manifesta-
tions in patients with mild to moderate depressive disorders 
shown in this study is important since, even in absence of a 
behavioral component, suicidal manifestations are a powerful 
predictor of future suicidal behavior.24,34
A meta-analysis of suicidal behaviors and ideation in 
clinical trials in depression with another SNRI, duloxetine, 
has also demonstrated the absence of any increased risk of 
suicidal behaviors or ideation during treatment with the SNRI 
compared with placebo.35
Discussion
Since major depression is present in at least 60% of patients 
who completed suicides, it seems reasonable to propose 
that a major objective in suicide prevention is related to the 
adequate treatment of depression.36 In a recent pharmaco-
epidemiological study, the authors estimated that prescribing 
antidepressants to all patients diagnosed with depression 
would prevent more than one out of three suicide deaths 
compared to the no antidepressants strategy, irrespective of 
age, gender or parasuicide history.37 However, a controversial 
issue concerning the potential risk of suicide associated with 
antidepressants generated numerous papers in the media and 
in the scientific literature. The consensual position that has 
emerged considers that a very careful assessment of suicide 
risk has to be performed before and after the initiation of 
the antidepressant. This improvement in quality of care 
should help to detect patients at risk, and to detect a potential 
emergence of suicidal risk particularly within the first weeks 
after the initiation of the antidepressant drug. Even if spe-
cific profiles of antidepressant drugs have to be investigated 
regarding this specific risk, the emergence or aggravation of 
suicidal risk may be conceptualized as an interaction between 
a specific antidepressant and a specific patient. In recent stud-
ies from the STAR*D and the GENDEP cohorts, it has been 
reported that depressed patients presenting an emergence of 
suicidal ideation when treated with antidepressants carried 
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specific genetic polymorphisms of CREB, glutamate related 
genes, BDNF, NTRK2.38–40 Moreover, in an imaging genet-
ics study, Perlis et al41 found that in healthy volunteers, the 
polymorphism of CREB associated with this specific suicidal 
phenotype was modulating the insular activity in aversive 
conditions. These data are promising as they complete the 
identification of vulnerability markers of suicidality, in this 
case in specific condition of antidepressant treatments, and 
because they emphasize the role of the ventromedial prefron-
tal cortex-related regions in the neuroanatomy of SB.
Studies should be performed using these specific bio-
markers in the development of new drugs, in order to inves-
tigate potential preventive effects on suicidal behavior, as 
well as potential deleterious effects.
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